These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 25953441)

  • 1. Widespread renal polycystosis induced by crizotinib.
    Di Girolamo M; Paris I; Carbonetti F; Onesti EC; Socciarelli F; Marchetti P
    Tumori; 2015 Jul; 101(4):e128-31. PubMed ID: 25953441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.
    Chun SG; Iyengar P; Gerber DE; Hogan RN; Timmerman RD
    J Clin Oncol; 2015 Feb; 33(5):e25-6. PubMed ID: 24616318
    [No Abstract]   [Full Text] [Related]  

  • 4. Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report.
    Madabhavi I; Patel A; Anand A; Panchal H; Parikh S
    Clin Respir J; 2018 Feb; 12(2):806-810. PubMed ID: 27606884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renal cysts - A novel complication of crizotinib treatment for lung cancer].
    CsToth I; Meert AP; Sculier JP; Berghmans T
    Rev Mal Respir; 2015 Nov; 32(9):956-8. PubMed ID: 26033699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer].
    Toffart AC; Sakhri L; Moro-Sibilot D
    Rev Pneumol Clin; 2013 Apr; 69(2):111-6. PubMed ID: 23561899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The renal effects of ALK inhibitors.
    Izzedine H; El-Fekih RK; Perazella MA
    Invest New Drugs; 2016 Oct; 34(5):643-9. PubMed ID: 27468827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.
    Brosnan EM; Weickhardt AJ; Lu X; Maxon DA; Barón AE; Chonchol M; Camidge DR
    Cancer; 2014 Mar; 120(5):664-74. PubMed ID: 24258622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
    Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
    Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical Efficacy of Crizotinib in Advanced ALK Positive 
Non-small Cell Lung Cancer].
    Zhao J; Zhang K; Zhang L; Wang H
    Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):616-20. PubMed ID: 26483333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Crizotinib treatment in a lung adenocarcinoma harboring ALK fusion gene with bone marrow metastasis: case report and literature review].
    Li X; Liu X; Gao F; Yin X
    Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):85-8. PubMed ID: 25676401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma.
    Sato Y; Fujimoto D; Shibata Y; Seo R; Suginoshita Y; Imai Y; Tomii K
    Jpn J Clin Oncol; 2014 Sep; 44(9):872-5. PubMed ID: 24966207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
    Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
    Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
    Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
    Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.
    Zhang Y; Yin J; Peng F
    Lung Cancer; 2017 Nov; 113():69-71. PubMed ID: 29110851
    [No Abstract]   [Full Text] [Related]  

  • 19. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
    Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
    Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.